AGAMREE® (vamorolone) oral suspension 40 mg/mL is corticosteroid FDA approved to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Skip to content Prescribing Information
AGAMREE produces reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, with the potential for the development of secondary adrenal insufficiency after withdrawal. Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal. The degree and duration of adrenocortical insufficiency
AGAMREE solution contains 40 mg/mL of vamorolone, the active ingredient of AGAMREE; therefore, the amount you withdraw into the oral syringe should be calculated by your healthcare provider or pharmacist
Learn about how AGAMREE® (vamorolone) oral suspension 40 mg/mL works to treat Duchenne muscular dystrophy (DMD) and see clinical study results in boys with DMD. Skip to content Prescribing Information
Patients should not take AGAMREE if they are allergic to vamorolone or any of the inactive ingredients in AGAMREE. What is the most important information I should know about AGAMREE? Do not stop AGAMREE, or change the amount taken, without first checking with your healthcare provider.
Available for new patients with DMD who are enrolled in the Catalyst Pathways program and have been prescribed AGAMREE. Some restrictions apply. Find financial assistance through a variety of programs
AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION Patients should not take AGAMREE if they are allergic to vamorolone or any of the inactive ingredients in AGAMREE.
AGAMREE ® (ah gam’ ree) (vamorolone) 40 mg/mL oral suspension . Read this Instructions for Use before you start using AGAMREE oral suspension and each time you get a new bottle. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Supplies provided in the AGAMREE carton:
AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION Patients should not take AGAMREE if they are allergic to vamorolone or any of the inactive ingredients in AGAMREE. Please see Important Safety Information throughout and
Along with supplementing existing DMD research with real-world information, the main focus of the AGAMREE SUMMIT Study is to better understand outcomes associated with long-term AGAMREE treatment, including bone health, behavior, sexual …